TRENDING TOPICS AND NEWS IN HCT AND CELLULAR THERAPY

Scientists believe lentiviral (LV)-based virus-like particles (VLPs) could improve chimeric antigen receptor (CAR) T-cell therapies and enable rapid, scalable production of gene-edited CAR T-cells...

Chimeric antigen receptor (CAR) T-cell therapy targeting CD19 and CD70 has the potential to improve outcomes in individuals with follicular lymphoma (FL) who have elevated relapse risk.

Graft-versus-host disease (GVHD) and non-relapse mortality (NRM) are possible after allogeneic hematopoietic cell transplantation (allo-HCT), but researchers say a recipient's pre-procedure...

Results from a retrospective investigation identified deletion (13q)/monosomy 13 (del[13q]/-13) as an independent risk factor for poor outcomes in multiple myeloma (MM) patients receiving upfront...

A retrospective European Society for Blood and Marrow Transplantation (EBMT) registry study characterized the late effects of autologous hematopoietic stem cell transplantation (aHSCT) for severe...

Phase I/II clinical evidence suggests Evomela may be a viable conditioning agent for multiple myeloma (MM) patients preparing for autologous hematopoietic stem cell transplantation.